Retroviral Vectors for Gene Therapy
Historically, retroviral vectors have been the most frequently used type of gene delivery vectors for clinical gene therapy. In particular, vectors based on murine leukemia virus (MLV) and related retroviruses have been employed in almost half of the current gene therapy clinical protocols (http://www.wiley.co.uk/genetherapy). The major advantages of retroviral vectors are (1) ease of manipulation for insertion of the therapeutic gene; (2) ability to stably integrate into the target cell genome; (3) relatively high titer of the recombinant retroviruses; (4) a wide range of target species and cells that can be infected without any apparent adverse pathology; and (5) relatively simple procedure for preparation of the recombinant virus. However, the current retroviral vector have potential disadvantages as well, such as (1) requirement for cell division for integration, limiting their in vivo applications; and (2) random integration into host chromosome, resulting in possible insertional mutagenesis or oncogene activation. However, recent developments in virus packaging systems, use of modified or different envelope proteins for packaging, and modifications with the cis-acting regulatory elements to regulate transgene expression have allowed for the safe and efficient clinical application of retroviral vectors. This chapter provides a background on retrovirus-based vector systems as well as provides an update regarding improvements in retroviral vector for gene transfer.
KeywordsLong Terminal Repeat Internal Ribosome Entry Site Murine Leukemia Virus Locus Control Region Internal Promoter
Unable to display preview. Download preview PDF.
- Challita, P.M., Skelton, D., el-Khoueiry, A., Yu, X.J., Weinberg, K., and Kohn, D.B. 1995, Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 69: 748.PubMedGoogle Scholar
- Ciafre, S.A., Barillari, G., Bongiorno-Borbone, L., Wannenes, F., Izquierdo, M., and Farace, M.G. 2002, A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo. Gene Ther. 9: 297.CrossRefPubMedGoogle Scholar
- Crittenden, M., Gough, M., Chester, J., Kottke, T., Thompson, J., Ruchatz, A., Clackson, T., Cosset, F.L., Chong, H., Diaz, R.M., Harrington, K., Alvarez Vallina, L., and Vile, R. 2003, Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy. Cancer Res. 63: 3173.PubMedGoogle Scholar
- Fassati, A., Bardoni, A., Sironi, M., Wells, D.J., Bresolin, N., Scarlato, G., Hatanaka, M., Yamaoka, S., and Dickson, G. 1998, Insertion of two independent enhancers in the long terminal repeat of a self-inactivating vector results in high-titer retroviral vectors with tissue-specific expression. Hum Gene Ther. 9: 2459.CrossRefPubMedGoogle Scholar
- Indraccolo, S., Minuzzo, S., Habeler, W., Zamarchi, R., Fregonese, A., Gunzburg, W.H., Salmons, B., Uckert, W., Chieco-Bianchi, L., and Amadori, A. 2000, Modulation of Moloney leukemia virus long terminal repeat transcriptional activity by the murine CD4 silencer in retroviral vectors. Virology. 276: 83.CrossRefPubMedGoogle Scholar
- Konishi, H., Ochiya, T., Chester, K.A., Begent, R.H., Muto, T., Sugimura, T., Terada, M., and Begent, R.H. 1998, Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody. Hum Gene Ther. 9: 235.CrossRefPubMedGoogle Scholar
- Leboulch, P., Huang, G.M., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y., and London, I.M. 1994, Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. EMBO J. 13: 3065.PubMedGoogle Scholar
- Loew, R., Selevsek, N., Fehse, B., von Laer, D., Baum, C., Fauser, A., and Kuehlcke, K. 2004, Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene. Mol Ther. 9: 738.CrossRefPubMedGoogle Scholar
- Morgan, R.A., Couture, L., Elroy-Stein, O., Ragheb, J., Moss, B., and Anderson, W.F. 1992, Retroviral vectors containing putative internal ribosome entry sites: Development of a polycistronic gene transfer system and applications to human gene therapy. Nucleic Acids Res. 20: 1293.CrossRefPubMedGoogle Scholar
- Ohashi, T., Boggs, S., Robbins, P.D., Bahnson, A., Patrene, K., Wei, F.S., Wei, J.F., Li, J., Lucht, L., Fei, Y., et al. 1992, Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and their functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc Natl Acad Sci U S A. 89: 11332.CrossRefPubMedGoogle Scholar